Current Report Filing (8-k)
March 10 2017 - 7:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 9, 2017
Seattle Genetics, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
0-32405
|
|
91-1874389
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
21823 30
th
Drive SE
Bothell, Washington 98021
(Address of principal executive offices, including zip code)
(425) 527-4000
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events.
On March 9, 2017, the Delaware Court of Chancery issued a temporary restraining order enjoining taking any action in furtherance of the closing of the
development and license agreement between Seattle Genetics, Inc. and Immunomedics, Inc. regarding sacituzumab govitecan (IMMU-132). The temporary restraining order will remain in place pending a hearing on an application for preliminary
injunction to be held in approximately thirty days.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SEATTLE GENETICS, INC.
|
|
|
|
|
Date: March 10, 2017
|
|
|
|
By:
|
|
/s/ Clay B. Siegall
|
|
|
|
|
|
|
Clay B. Siegall
President and Chief Executive Officer
|
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024